Profil:
Selvita SASelvita pharma backlog for 2025 at PLN 249.9 mln
Pharma firm Selvita's backlog for 2025 remains at a similar level to the same period last year and amounts to PLN 249.9 million (EUR 58.9 mln), the company said in a press release.
The structure of the backlog shows, among other things, a 7 percent increase in the drug development segment and a 3 percent increase in normalised contracting in the drug discovery segment.
"As announced, we entered 2025 with a lot of upside momentum, which can be seen in the first quarter results. However, the turbulence in the US market as a result of the new administration's decisions in the first few months has introduced enough uncertainty that even the optimistic venture capital fund investment figures recently do not yet provide sufficient grounds to speak of a trend reversal and translate this into our business," said, quoted in the press release, CEO Boguslaw Sieczkowski.
"We are continuing our intensive sales activities, and at the same time optimising operations in order to best navigate the demanding market," he added.
As reported, the group is observing the increasing efficiency of PozLab (drug development segment), acquired a year ago, and maintains the expectation that it will start to contribute positively to the consolidated operating result by the end of this year at the latest.
doa/ nl/